【缺藥訊息】 公告日期：2023/11/24。 缺藥品項：Ebixa 錠劑 10mg。 缺藥原因：因經銷轉移問題缺貨，恢復供貨時間未知。 替代藥品：國內有同成份規格替代品。 配套措施：採購替代品，庫存量用罄關檔停用，替代品預計於 12/5 前到貨。

Alzheimer's disease (Moderate to Severe)

Memantine hydrochloride is a low to moderate affinity, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist which binds to NMDA receptor-operated cation channels. Memantine also blocks the 5-hydroxytryptamine-3 receptor (at a potency similar to the NMDA receptor) and nicotinic acetylcholine receptors (at one-sixth to one-tenth the potency). However, memantine has low to negligible affinity for gamma-aminobutyric acid, benzodiazepine, dopamine, adrenergic, histamine, and glycine receptors and for voltage-dependent calcium, sodium, or potassium channels.

Bioavailability: approximately 100%; plasma protein binding: 45%; Excretion: 48-50% excreted unchanged in the urine; Elimination Half-life: 60-80 hrs

Hypersensitivity to the active substance or to any of the excipients.

B [FDA]

Infant risk cannot be ruled out. [MDX]

dizziness (most common), headache, confusion, somnolence, constipation, vomiting, cough

Initial, 5 mg orally once daily; increase dose at minimum 1 week intervals in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg in separate doses), and 20 mg/day (10 mg twice daily); target daily dose is 20 mg/day.

(CrCl of 30 to 80 mL/min): No dosage adjustment necessary; (CrCl, 5 to 29 mL/min): Immediate-release, reduce dosage to 5 mg PO BID; extended-release, reduce dosage to 14 mg PO QD

Hepatic impairment, severe: Administer with caution